k8凯发

Company Updates

Hemogen’s Hemocel (HGI-001 Injection) Receives ThaiFDA Clinical Trial Approval and Successfully Completes Manufacturing Equipment Transfer Validation

Shenzhen Hemogen Therapeutic Co., Ltd. (hereinafter referred to as “Hemogen”) has achieved a significant milestone in its international...

BGI Group Leads Advancements in Tackling Thalassemia

Thalassemia is a rare, inherited blood disorder caused by mutations in the genes involved in hemoglobin production that cause the body to produce less...

Exciting News: Hemogen Recognized as "Future Industry Enterprise in the Field of Cellular and Genetic Technologies" in Yantian District!

Recently, the Science and Technology Innovation Bureau of Yantian District, Shenzhen, issued the "Interim Measures for the Recognition and Manage...

Exciting News: Hemogen's HGI-001 Injection Drug IND Approved!

On December 19, 2023, Hemogen Biotechnology Co., Ltd. (Hemogen), based in Shenzhen, successfully obtained the IND（investigational new drug) approval f...

Chao Liu ,CEO of Hemogen, Attends China-Indonesia Business Forum

On October 16th, during the visit of Indonesian President Joko Widodo to China and his attendance at the third Belt and Road International Cooperation...

Dr. Chao Liu, CEO of Hemogen, was Invited for Visit to Indonesia

Upon the invitation of KALBE, Indonesia's largest pharmaceutical company, and innovative biopharmaceutical company Etana Biotechnologies, Dr. Chao...

Gene Therapy for Thalassemia Lands in Malaysia, Bringing Hope for Patients

On October 10, 2023, CG Therapeutics Private Limited (CGT) and Hemogen HongKong Alpha Technology Limited, a subsidiary of Hemogen (Hong Kong), officia...

Four-Party Strategic Agreement! Hemogen and Mahidol University Join Forces to Advance Thalassemia Gene Therapy in Thailand

On July 18th, Dr. Chao Liu, CEO of Hemogen, Mr. Preecha Laohapongchana, Director of Xingtai Genetics, Dr. Apichat Asavamongkolkul, Dean of the Faculty...

Previous 1 2 Next

info@winsapk.com